Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clover Health Investments

Corsair Gaming

LifeMD 

Nokia

VanEck Vectors Social Sentiment ETF

FOMO ETF

These seven meme stocks to buy could be good picks for July as investor interest in these high-risk, high-return plays continues to grow. The post 7 Meme Stocks to Buy for Their ‘To-the-Moon' Potential  appeared first on InvestorPlace.

7 Meme Stocks to Buy for Their ‘To-the-Moon' Potential

Ocugen Inc. (NASDAQ: OCGN) shares traded higher Tuesday after the company announced that its coronavirus vaccine co-development partner Bharat Biotech reported Phase 3 results demonstrating 77.8% protection against overall disease.  Ocugen was up 6.45% at $7.76 at last check.

What's Next For Ocugen Stock As It Nears Key Resistance Level?

OCGN stock has been counted out of the vaccine race many times, but there is plenty of room for optimism moving forward. The post 3 Reasons Ocugen Stock Should Maintain Its Upward Trajectory appeared first on InvestorPlace.

3 Reasons Ocugen Stock Should Maintain Its Upward Trajectory

Ocugen's Indian vaccine development partner reported better-than-expected results from its local Covid-19 vaccine trials. OCGN stock has been on a roller-coaster ride on every Covaxin rumor and news item.

OCGN Stock: The Big Covaxin News That Has Ocugen Rallying Today

Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to press ahead with plans to file for approval of their COVID-19 vaccine, Covaxin, in the U.S. and Canada. Covaxin has already been approved for restricted emergency use in India, getting the green light in January months before the final results from the trial were available.

Ocugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%

While the contrarian bullish argument for OCGN stock has picked up considerable chatter, this is an extremely risky trade. The post Don't Play the Ocugen Stock Short Squeeze Before You Read This Warning!

Don't Play the Ocugen Stock Short Squeeze Before You Read This Warning!

Ocugen was a penny stock is up 180% for the year.  But all good things must come to an end.

Ocugen Has Had a Good Run, but the Math Says It's Over

Antares Pharma

GT Biopharma Inc

ObsEva

Odonate Therapeutics

Palatin Technologies

Seelos Therapeutics

Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.

7 Penny Stocks For Your Watch List This Week If You Like Biotech In July

It may equal some coronavirus vaccine revenue ahead.

One Bright Spot for Ocugen Investors

MALVERN, Pa., and HYDERABAD, India, July 02, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its co-development partner, Bharat Biotech, shared positive results of its Phase 3 study of COVAXIN™, a whole virion inactivated COVID-19 vaccine candidate.  COVAXIN™ demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 77.8% with efficacy against severe COVID-19 disease alone of 93.4%.

Ocugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease

Carnival

ChargePoint Holdings

Chewy

Doximity

NVIDIA

Shopify

These stocks to sell have stretched valuation, but their fundamentals are robust and these stocks are worth accumulating on a correction. The post 7 Stocks to Sell as You Head Into July 2021 appeared first on InvestorPlace.

7 Stocks to Sell as You Head Into July 2021

SAN DIEGO--(BUSINESS WIRE)-- #OCGNstock--The suit alleges defendants issued false statements concerning Ocugen business and prospects, resulting in its stock trading at inflated prices.

Opportunity for Investors With Substantial Losses to Lead the Ocugen, Inc. Class Action Lawsuit - OCGN

The U.S. vaccine market has slipped farther out of reach.

How Risky Is Ocugen After Its Recent Setback?

Both have the necessary ingredients for explosive short-squeeze returns.

Better Short-Squeeze Stock: Clover Health or Ocugen?

It could be due to the aftereffects of being included in a major stock index.

Why Ocugen Shares Are Slipping Today

The bad news with Covaxin hasn't sunk in yet with OCGN stock investors, so get out while the stock still remains elevated. The post Sell Ocugen Stock Before the Other Shoe Finally Drops appeared first on InvestorPlace.

Sell Ocugen Stock Before the Other Shoe Finally Drops

Ocugen Inc (NASDAQ: OCGN) shares are trading 1.6% higher in the pre-market session on Wednesday amid high social media interest. The company's shares had closed nearly 2% lower at $8.46 in the regular session, the day prior.

What's Going On With Ocugen (OCGN) Stock Today?

NEW YORK--(BUSINESS WIRE)-- #OCGN--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive (the “Class Period”), of the important August 17, 2021 lead plaintiff deadline. SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To

ROSEN, A LEADING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important August 17 Deadline in Securities Class Action – OCGN

The class-action lawsuits against Ocugen are getting prepared by lawyers. Trading at $8.35, OCGN stock looks ready to take a fall.

If Ocugen Stock Is Worth $8, I'll Eat My Hat

NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) and certain of its directors on behalf of shareholders who purchased or otherwise acquired Ocugen securities between February 2, 2021 and June 2, 2021 (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/ocgn. This class ac

OCGN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ocugen, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

OCGN stock is of no value to investors now that federal regulators closed the door on its Covid-19 vaccine commercialization efforts. The post Ocugen Stock Is A Bust After Covaxin's Emergency Use Rejection appeared first on InvestorPlace.

Ocugen Stock Is A Bust After Covaxin's Emergency Use Rejection

After OCGN stock rallied due to factors that were not based on fundamentals, investors should sell the shares. The post Get Rid of Ocugen Stock While You Can as the Bad News Piles Up appeared first on InvestorPlace.

Get Rid of Ocugen Stock While You Can as the Bad News Piles Up

NEW YORK, June 25, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive (the "Class Period"), of the important August 17, 2021 lead plaintiff deadline. SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action - OCGN

Ambev

ENGlobal

Invesco Mortgage Capital

Kelso Technologies

Progenity

Uranium Energy

With July only a week away, which penny stocks are investors watching right now? The post Hot Penny Stocks to Buy in 2021?

Hot Penny Stocks to Buy in 2021? Check These 7 Out Right Now

The company will join a rarefied club starting early next week.

News for Ocugen, Inc. Stock (OCGN)